Efficient production of eukaryotic expression vectors requires the selection of plasmidcontaining bacteria. To avoid the risk of dissemination of antibiotic resistance markers, we developed a new system to produce a family of plasmids Free of Antibiotic Resistance genes, called pFARs. The strategy is based on the suppression of a chromosomal nonsense mutation by a plasmid-borne function. The amber mutation was introduced into the Escherichia coli thyA gene that encodes a thymidylate synthase required for dTMP synthesis, resulting in thymidine auxotrophy. In parallel, a small plasmid vector that carries an amber suppressor t-RNA gene was entirely synthesised. The introduction of pFAR plasmids into an optimised thyA mutant restored normal growth to the auxotrophic strain, and led to an efficient production of monomeric supercoiled plasmids, as required for clinical trials. Luciferase activities measured after intramuscular injection and electrotransfer of LUC-encoding pFAR vector were similar to those obtained with a commercial vector containing the same expression cassette. Interestingly, whereas luciferase activities decreased within three weeks after intradermal electrotransfer of conventional expression vectors, sustained levels were observed with the pFAR derivative. Thus, pFAR plasmids represent a novel family of biosafe eukaryotic expression vectors, suitable for gene therapy.
Introduction
High expression levels of therapeutic proteins in transfected mammalian cells require an optimal intracellular gene delivery. Although viral vectors are considered to be efficient vehicles for gene transfer, their use is restricted by several major limiting factors, such as the occurrence of immune responses to viral components, possible insertional mutagenesis into host genome and high production costs. [1] [2] [3] [4] These drawbacks can be avoided by using easily produced non-viral expression vectors that remain in episomal state inside eukaryotic cells. 5, 6 Furthermore, the development of physical methods (e.g: hydrodynamic delivery or electrotranfer) used to administer plasmids in vivo, allowed a significant increase in protein expression levels 7, 8 and reconsidering non-viral expression vectors as therapeutic gene vehicles.
Non-viral expression vectors consist of three main classes: plasmidic DNA, MIDGE vectors, 9 and minicircles. [10] [11] [12] The two last ones are produced from a parental plasmid, which contains a eukaryotic expression cassette flanked by either restriction enzyme-or recombinaserecognized specific sequences, respectively. After plasmid propagation, the expression cassette is released by either enzymatic digestion or intramolecular recombination and further purified. [9] [10] [11] [12] MIDGE vectors and minicircles present the main advantage of being totally free of bacterial sequences that seem to promote heterochromatin formation, leading to gene silencing in certain organs such as liver. 13 In muscles, however, prokaryotic sequences do not appear to impair prolonged gene expression, 5 promoter/operator region 14, 15 (ii) a suppressor t-RNA coding sequence enabling complete traduction of a protein playing a role in the arginin biosynthetic pathway 16, 17 (iii) a replication origin encoding an RNA molecule involved in the regulation of an essential E. coli gene via an RNA/RNA interference mechanism. 18, 19 In this paper, we describe a novel combination E. coli producer strain / plasmids Free of Antibiotic Resistance markers, referred as pFARs. On one side, a nonsense mutation (CAT → TAG) was introduced into the essential E. coli thyA gene that encodes a thymidylate synthase, an enzyme required for DNA precursor synthesis. The thyA mutant was further optimised for the production of a family of new and small pFAR vectors that encode an amber suppressor t-RNA. Finally, pFAR efficiency as eukaryotic expression vectors was assessed using the luciferase reporter gene expressed from the cytomegalovirus (CMV) promoter, after plasmid injection into muscle and skin, followed by electrotransfer. This physical method consists of applying electric field-mediated intracellular delivery via a mechanism mostly composed of cell permeabilisation and DNA uptake through electrophoresis, allowing an increase in protein expression level by a two-log factor in both organs.
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Results
Description of a novel combination of an E. coli producer strain / plasmids devoid of Antibiotic Resistance Markers
To propagate plasmids free of antibiotic resistance markers, a nonsense mutation (TAG) was introduced into the E. coli thyA gene that encodes a thymidylate synthase (EC 2.1.1.45). This enzyme is required for de novo synthesis of thymidine monophosphate (dTMP) from deoxyuridine monophosphate (dUMP). Mutation in thyA leads to thymidine auxotrophy 23 that can be overcome by adding exogenous thymidine in the growth medium. The supplement penetrates into bacterial cells, via a nucleoside transporter, and is transformed into dTMP by a thimidine kinase (EC 27.1.75). In the absence of thymidine, only the strains that contain a plasmid encoding a suppressor t-RNA enabling full traduction of ThyA can grow ( Fig. 1 ).
An amber mutation, which substitutes the CAT encoding His147 to TAG, was introduced into the cloned thyA region and subsequently inserted into the non-pathogenic E. coli strain MG1655 genome by homologous recombination. The selected mutant did not grow on minimal medium unless thymidine was added. To facilitate cloning procedures and plasmid preparations for routine laboratory assays, we identified another selective complex medium:
the Mueller Hinton (MH) broth known to contain only traces of thymidine 24 and in which the thyA mutant did not grow.
In parallel, a plasmid devoid of antibiotic resistance markers was constructed. First, the histidine suppressor t-RNA gene was introduced into pVAX2, an expression vector that carries a kanamycin resistance gene. 25 The suppressor t-RNA gene is an allelic form of hisR, which codes a histidine t-RNA with a modified anticodon (AUG → CUA) followed by two AA to yield 5 ' CUAAA. This additional modification was shown to improve the suppression efficiency of the nonsense mutation. 26 Expression of the t-RNA suppressor is under the control of the E. coli lipoprotein promoter region (lpp) and the transcription terminator sequence from the rrnC operon, 27 two cis-regulatory elements only active in prokaryotic cells.
The kanamycin resistance gene was subsequently deleted from pVAX2.sup.t-RNA and the resulting plasmid, Free of Antibiotic Resistance marker, was called pFAR1. To validate the proposed strategy, pFAR1 was introduced into the thyA mutant by transformation. Whereas no bacteria electroporated with water appeared on selective medium (MH), pFARtransformed cells grew well even in the absence of thymidine, indicating that the suppression of the nonsense mutation could sustain bacterial growth. Plasmid DNA were prepared from several transformants grown overnight in selective medium. They all appeared to contain pFAR1, with the expected size and restriction profiles. All these data showed that this novel combination of E. coli thyA mutant / pFAR plasmid can be used to produce plasmids devoid of antibiotic resistance markers and was therefore further optimised.
Optimisation of the bacterial producer strain and of the expression eukaryotic vector
The use of plasmid DNA for clinical trials requires that they meet some defined criteria such as purity and topology. 28, 29 As most laboratory strains contain suppressor t-RNA genes, the amber mutation had to be introduced into the wild-type reference strain MG1655. To reach optimal conditions for plasmid production, the thyA mutant needed therefore to be further optimised. DNA quality produced by bacterial strains can be improved by mutating the endA gene that encodes the endonuclease 1. Although the function of this enzyme is not fully understood, the quality of plasmid DNA purified from endA+ strains appears inconsistent, degrading upon long-term storage. 30 To overcome this, an internal region of endA (coding amino acids 7-234 of the 234 AA-long EndA protein) was deleted from the thyA mutant chromosome, to give a double thyA endA mutant.
During plasmid propagation and replication, intermolecular recombination between homologous sequences can occur, leading to multimers formation and increase in plasmid size. Plasmid copy number being controlled by the replication origin concentration, recombination events will have an influence on the monomers/multimers ratio, resulting in inconsistency from one plasmid batch to another, which is not suitable for pharmaceutical applications. 28, 29 To avoid multimers formation, the internal region of recA that encodes a recombinase (353 amino-acids) was deleted (AA: 5-343) from the double thyA endA mutant genome. As shown Figure 2a , plasmids prepared from the triple mutant predominantly formed monomeric closed circular DNA whereas those purified from the simple thyA mutant also appeared as dimers or multimers.
Having optimised the bacterial producer strain, our next objective was to further develop the plasmid vector. To minimize bacterial sequences and plasmid size, a new DNA vector was entirely synthesised and called pFAR4 (Fig. 3 ). pFAR4 has a small size (1.1-kb), it contains a pUC-type origin of replication, the same histidine suppressor t-RNA gene as pFAR1 and a multiple cloning site to allow easy cloning procedures. When introduced into the triple thyA endA recA mutant, pFAR4 showed the same properties as pFAR1 such as the ability to restore normal growth to the thymidine auxotrophic strain. In selective MH medium, the growth curve of the optimised thyA mutant containing a pFAR4 derivative was similar to that of the strain DH5α harbouring pVAX2-LUC propagated in the presence of kanamycin (Fig. 2b) .
Furthermore, at a similar optical density (OD600~0.9) or after overnight growth, the amount of pFAR4 plasmids purified from the triple thyA endA recA mutant was equivalent to that of a pVAX2 derivative prepared from DH5α grown in LB medium supplemented with kanamycin ( Fig. 2c) . Thus, bacterial and plasmid optimisation led to the production of plasmids devoid of antibiotic resistance markers with a good yield and appropriate criteria for in vivo studies.
8
Assessment of pFAR plasmids as eukaryotic expression vectors
To assess whether pFAR plasmids could be used for in vivo studies, the cytoplasmic firefly luciferase-encoding gene was cloned into pFAR1 and pFAR4 (Fig. 3) . The reporter gene is under the control of the ubiquitous cytomegalovirus (CMV) promoter and the bovine growth hormone (BGH) polyadenylation signal. Plasmids pVAX2-LUC, pFAR1-LUC and pFAR4-CMV LUC BGH, which contain the same expression cassette, were injected into mouse tibial cranial muscles and subsequently electrotransferred. Luciferase activities were determined after intraperitoneal injection of the substrate, luciferin, using a charged-coupled device (CCD) camera that allows monitoring gene expression in living animals (Fig. 4) . Until day 15, luciferase activities recorded after injection of either plasmids were similar, indicating that pFAR1 or the newly synthesised vector pFAR4 do not exert adverse effects after muscle transfection. At later time points, however, luciferase activities started decreasing in some mice. When sera were collected by retro orbital puncture, they appeared to contain antibodies directed against the exogenous luciferase protein.
In the mouse showing a great decrease in luciferase activity, the amount of anti-LUC antibodies was of 14.5 μg/ml 30 days after plasmid injection, and reached 70 μg/ml at day 60.
To assess luciferase expression in another tissue, pVAX2-LUC and pFAR4-CMV LUC BGH were then injected into mouse skin and electrotransferred. Figure 5 shows that luciferase activities in pVAX2.LUC-transfected cells decreased within a few weeks time. In marked contrast, the injection of the pFAR derivative led to sustained luciferase expression levels. In another experiment, a prolonged expression in skin cells was observed for more than three months (data not shown).
Discussion
Production of recombinant therapeutic proteins or of plasmids most often implies growing bacteria in the presence of antibiotics to ascertain vector maintenance and propagation in prokaryotic cells. To avoid the risk of dissemination of antibiotic resistance markers to mammalian-colonizing endogenous flora and/or putative anaphylactic chocks due to the presence of these compounds in plasmid preparations, we developed a new system to produce plasmids Free of Antibiotic Resistance genes referred as pFARs. The strategy is based on the suppression of a nonsense amber mutation introduced into the essential E. coli thyA gene by a plasmid encoding a suppressor t-RNA.
Nonsense mutations are of three types: amber, ochre or opal, resulting in UAG, UAA or UGA chain-terminating codons, respectively. We chose to introduce an amber nonsense codon into the thyA gene for two main reasons: (i) several studies have shown that amber mutations can be efficiently suppressed 26, 27, 31 and (ii) the distribution of translation termination codons is as follows: 7.6% for UAG, 63% for UAA and 29.4% for UGA. 32 Thus, the introduction of UAG suppressor t-RNA into E. coli was expected to have a moderate impact on host metabolism. This is also supported by the fact that most laboratory strains and a significant number (~30%) of wild-type E. coli isolates naturally contain amber suppressor t-RNA genes, with no apparent selective disadvantage. 33, 34 Furthermore, all amber mutations are not suppressed with an equal efficiency. Several factors seem to play a role, such as the nucleotides surrounding the nonsense codon being suppressed 26 as well as the selected suppressor t-RNA. 26, 27, 31 Taking into account all of these parameters and work reported by Michiaels et al 35 on the insertion of nonsense codon in the thymidylate synthase coding region, we chose to introduce the amber mutation in the thyA nucleotide sequence encoding histidine 147, which lies in the substrates binding pocket of the enzyme. 35 This mutation resulted in thymidine auxotrophy that could be efficiently suppressed upon introduction of pFAR4.
pFAR4 is a new plasmidic DNA vector that was entirely synthesised. It carries an allelic form of hisR, the expression of which is under the control of prokaryotic regulatory elements, and encoding a histidine suppressor t-RNA that allows the insertion of the expected amino acid with a high efficiency (up to 100%). 26, 35 Indeed, the introduction of pFAR plasmids into the optimized thyA mutant allowed the selection of plasmid-containing bacteria, restoration of a normal growth to thymidine auxotrophic strains and high yield production of monomeric 
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Sustained luciferase expression observed in pFAR derivative-transfected skin cells was somehow unexpected as, it had, to our knowledge, never been observed before. 37 There exist a few differences between pVAX2-LUC and pFAR4-CMV-LUC-Bgh: (i) pVAX2-LUC is ~0.9-kb bigger ( Fig. 3 ) and (ii) it contains 12 additional CpG motifs that are potential inflammatory hexanucleotides made of CG flanked by two purines and two pyrimidines. 38, 39 Furthermore, whereas pVAX2-LUC harbours one GACGTT motif (Fig. 3) , which was reported to have the most immunostimulatory effect in mice, 39,40 the pFAR4 derivative carries none. Co-injection of pFAR4 with an immunostimulant CpG oligonucleotide (ODN 1668) 39, 40 did not influence temporal luciferase gene expression in skin (our unpublished data). Further 11 analyse will be performed to determine the factors playing a role in the sustained gene expression level as well as the type of transfected skin cells. Anyhow, this interesting property of pFAR vectors may allow using skin cells to secrete therapeutic proteins at several defined sites but at a low dose, which might be beneficial for some applications. For high expression levels, skeletal muscle might be a better target as it represents a long life span organ with a large volume of accessible tissue capable of producing local and systemic factors. 41 Thus, pFAR plasmids appear to be efficient eukaryotic expression vectors suitable for the delivery of therapeutic genes and the treatment of a large range of human diseases. Our next objective is to assess this feasibility.
Materials and methods
Microbiological and Molecular Biology manipulations
Escherichia coli strains were grown in either complex (Luria-Bertani 42 or Mueller Hinton 43 (Sigma-Aldrich, Lyon, France)) or minimal (M9) 42 media supplemented with either antibiotics 42 or thymidine (30 μg/ml). The DH5α strain 44 was used for routine cloning procedures that were carried out as described in Sambrook et al.
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E. coli mutants were isolated from strain MG1655 obtained from "The Coli Genetic Stock
Center" (USA) (http://cgsc.biology.yale.edu) since, unlike most laboratory strains, it does contain suppressor t-RNA alleles (Accession number #U00096).
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Construction of E. coli mutants E. coli mutants were isolated essentially as described by Posfai et al. 45 using pST76-C to introduce mutated genes into the bacterial genome, and pST76-AsceP to select those strains in which the second event of recombination had occurred. Both plasmids have a thermosensitive origin of replication and are therefore easily cured from bacteria by growing them at 43°C in the absence of antibiotics.
To construct the thyA mutant, a 2-kb region covering the thyA gene was amplified by PCR using the ExTaq polymerase (Takara, Lonza, Verviers, Belgium), MG1655 genomic DNA and primers (ThyA-F: CATGCGGTATTGCGCAGGC and ThyA-R:
CGCTGTATCTGTTCCGTGTCT). The primers were designed to place the amber mutation in the centre of the 2-kb fragment. The PCR product was ligated to the cloning vector PCR2.1 (Invitrogen, Illkirch, France) and sequenced. An amber mutation (His 147: CAT→TAG) was introduced into the thyA gene by site directed mutagenesis using the QuikChange® II SiteDirected Mutagenesis Kit (Stratagene, La Jolla, CA, USA) and ThyA-His147-F
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(CGCTGGCACCGTGCTAGGCATTCTTCCAGTTC) and ThyA-His147-R (GAACTGGAAGAATGCCTAGCACGGTGCCAGCG) as primers. The mutated thyA region was then entirely sequenced to ascertain that the insert only contained the amber mutation.
Plasmids PCR-thyA* and pST76-C were ligated after digestion by EcoRV and SmaI, respectively. Finally, the pUC replication origin from pCR2.1 was deleted by digesting the fusion plasmid by BamHI. The mutated thyA region was then introduced into the MG1655 genome as described above, selecting for thymidine auxotrophic strains. Amplification by PCR of a 2.6-kb fragment covering the mutated region and sequence analysis confirmed that the mutated strain only contained an amber mutation in thyA and that the adjacent genes have not been affected by the crossing-over events.
To construct the double thyA endA mutant, two 1-kb fragments, covering regions upstream (yggI) and downstream (rsmE) from endA, were amplified by PCR using MG1655 genomic DNA as a template, the ExTaq polymerase (Takara, Lonza, Verviers, Belgium) and two pairs of primers (GTCGGTTTTGCCATGAGTGC and tacccgggTAGACAAATAACGGTACATCAC) and (ttcccgggAGAGCTAACCTACACTAGCG and CCACTCTTCGTAGTTCTGCT), respectively. The PCR fragments were entirely sequenced after cloning into PCR2.1 (Invitrogen, Illkirch, France). The 1-kb SmaI-XbaI fragment from PCR2.1-yggI was ligated to PCR2.1-rsmE digested with SmaI-SpeI, to give PCR2.1 delta endA. This latter plasmid (digested with ApaI and Klenow-treated) was fused to pST76-C (digested with SmaI). A BamHI deletion gave a plasmid only carrying the thermosensitive replication origin. The deleted endA region was introduced into the thyA mutant genome as described above.
To construct the triple thyA endA recA mutant, two 1-kb fragments located upstream (ygaD) and downstream (recX) from recA were amplified by PCR using the MG1655 genomic DNA as a template, the ExTaq polymerase (Takara, Lonza, Verviers, Belgium) and two pairs of primers (GTAATGGCAAACGGTCAGGC and gatcccgggGTCGATAGCCATTTTTACTCC) and (catcccgggGAAGGCGTAGCAGAAACTAAC and GTCGCCGAAGCTGAAGTTG), respectively. ygaD and recX were fused using the same protocol as previously described.
PCR2.1.delta.recA was ligated to pST76-C after digesting the plasmids with XbaI (Klenowtreated) and SmaI, respectively. The deleted recA region was introduced into the thyA endA mutant as described above.
Construction and preparation of pFAR plasmids
Plasmids that are Free of Antibiotic Resistance markers are called pFARs. pFAR1 is a derivative of pVAX2 25 that was obtained by replacing the cytomegalovirus promoter of pVAX1 (Invitrogen, Illkirch, France) by that of pCMV-β (Clontech, Ozyme, Saint-Quentinen-Yvelines, France). The Histidine t-RNA suppressor gene was amplified from pGFIB-1.His(AS) 31 by PCR using primers (gtccatggCTGGCGCCGCTTCTTTGAGC and ccccatggACGACGGCCAGTGCCAAG). The PCR fragment was digested with NcoI and inserted into pVAX2 digested with BspHI. The digestion of the resulting plasmid by HindIII (Klenow-treated) and PvuII, followed by a self-ligation, allowed the deletion of the kanamycin resistance gene, to give pFAR1.
To construct pFAR1-LUC, the 1.7-kb BamHI-XhoI fragment containing the firefly cytoplasmic luciferase-encoding gene was isolated from pVAX2-LUC 25 and introduced into pFAR1 digested with the same enzymes. To optimise the expression vector, a new plasmid, called pFAR4, was entirely synthesised (Geneart, Regensburg, Germany). The ~1.7 kb MluIPvuII fragment containing the expression cassette CMV-LUC-BGH cleaved from pVAX2-LUC was introduced into pFAR4 digested with MluI and EcoRV, to give pFAR4-CMV LUC BGH.
For in vivo studies, plasmids were purified using Endofree preparation kits (Qiagen, Hilden, Germany). Endotoxin levels were determined by Lonza (Verviers, Belgium), using the LAL procedure. They were all below the detection limits (< 0.05 EU/ml). The quality of plasmids was assessed by calculating the ratio of light absorption (260 nm/280 nm) and by visualisation on Ethidium Bromide-stained 1% agarose gels. Light absorption at 260 nm was used to determine DNA concentration.
in vivo studies 6-8 weeks old female BALB/c mice (Charles River, L'Arbresle, France) and 6 weeks old female NMRI mice (Université catholique de Louvain, Brussels, Belgium) were used for plasmid intramuscular and intradermal injection, respectively. Prior to all procedures, the animals were anaesthetised by intraperitoneal injection of ketamine and xylazine as described by Bloquel et al. 36 and Vandermeulen et al. 20 . Studies were conducted following the mg/100 μl). Optical imaging was acquired using an IVIS50 system (Xenogen corporation, Alameda, CA, USA). The duration of luminescence acquisition was between 10 s and 60 s and was initiated 10 minutes after injection of the substrate. In both cases, luminescence levels were integrated in region of interest (ROI) drawn by hand around luminescence zones.
Background luminescence was subtracted according to values obtained in ROI drawn on a non-transfected zone of the mice. 36 
Titration of anti-LUC antibodies
Antibodies against luciferase in mouse serum were titrated by ELISA, essentially as described by Bloquel et al, 36 using luciferase (E1702, Promega, Madison WI, USA) to coat the microplates and a horseradish peroxidase-conjugated goat anti-mouse secondary antibody (NXA931, GE Healthcare, Uppsala, Sweden). To establish a standard curve, a serial dilution of a monoclonal antibody anti-luciferase (L2164, Sigma-Aldrich, Lyon, France) was used. Figure 1 . Description of the strategy used to propagate pFAR plasmids. A nonsense mutation TAG was introduced into the E. coli thyA gene, resulting in thymidine auxotrophy.
Titles and legends to figures
The mutant strain was isolated in the presence of thymidine that can penetrate into bacterial cells where it is transformed into dTMP, a precursor required for DNA polymerisation. In selective medium, only the strains containing a plasmid encoding a suppressor t-RNA i.e.
inserting an amino acid in response to UAG can grow. and electrotransferred into the skin of 7 or 8 mice. Luciferin was injected intraperitoneally, 1, 3, 6, 9, 14 or 21 days later and luciferase activities were monitored using a CDD camera.
Bars represent the mean values (± SEM).
